Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Vitae Pharmaceuticals begins phase IIa trial of VTP-38543 in atopic dermatitis

Dec. 14, 2015

Fuji Chemical Industry develops carotenoid derivatives

Dec. 11, 2015

Samumed reports preliminary efficacy data from phase II study of SM-04554 for androgenetic alopecia

Dec. 9, 2015

Foamix reports topline results from phase II study of FDX-104

Dec. 9, 2015

Almirall announces strategic acquisition of dermatology products

Nov. 26, 2015

Alexar Therapeutics initiates phase IIa trial of ALX-101 for atopic dermatitis

Nov. 26, 2015

Roivant Sciences licenses PDE4 inhibitor E-6005 from Eisai

Nov. 25, 2015

CHMP recommends approval of Episalvan to treat partial thickness wounds in adults

Nov. 24, 2015

Hapten Sciences plans phase I trial of urushiol vaccine

Nov. 23, 2015

miRagen Therapeutics begins first clinical trial for antifibrosis candidate MRG-201

Nov. 16, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...